Madrid

• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504799-94-00 4 2024-02-20 Chronic Spontaneous Urticaria
• A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 … Ended
  2023-506354-20-00 1 2024-02-20 Small Cell Lung Cancer and Neuroendocrine Carcinoma
• A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liv … Ended
  2023-506083-13-00 4 2024-02-16 clinically significant portal hypertension (CSPH) in decompensated cir
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M … Ended
  2023-507321-42-00 1 2024-02-15 Myelodysplastic syndrome (MDS)
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors Ended
  2023-504896-26-00 1 2024-02-09 Advanced Stage Solid Tumors
• THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICA … Ended
  2023-507304-32-00 6 2024-02-09 Chronic Obstructive Pulmonary Disease
• Randomised, crossover bioavailability clinical trial of oral minoxidil 1 mg, after single and multiple dose administration to healthy volunt … Ended
  2023-503796-14-00 3 2024-02-01 Androgenetic alopecia
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 4 2024-01-29 ER-positive/HER2-negative early breast cancer
• A study to evaluate efficacy and safety of SAR441566 in adults with plaque psoriasis Ended
  2023-503911-14-00 4 2024-01-25 Psoriasis
• A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) Ended
  2023-503502-37-00 4 2024-01-24 Non segmental vitiligo
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN Ended
  2023-505796-76-00 3 2024-01-18 Locally Advanced Squamous Cell Carcinoma of the Head and Neck
• RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BAS … Ended
  2023-509075-17-00 4 2024-01-17 Bacilliferous pulmonary tuberculosis
• MK-0616-013 Ended
  2022-502777-42-01 5 2024-01-16 Hypercholesterolemia
• A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended
  2023-503183-16-00 4 2024-01-16 Systemic Lupus Erythematosus
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Phase 2a Study to Evaluate Setanaxib in Patients with Alport Syndrome Ended
  2023-505292-73-00 4 2024-01-10 Alport syndrome
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 7 2024-01-09 HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Adva
• Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Ended
  2023-503919-15-00 3 2024-01-09 Prostatic Neoplasms
• A Phase 2 Multicenter Study to Evaluate PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations Ended
  2023-503343-33-00 4 2023-12-21 Active Cutaneous Lupus Erythematosus (CLE) or Systemic Lupus Erythemat
• A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul … Ended
  2023-505487-11-00 5 2023-12-21 Actinic Keratosis on the Face or Scalp

Showing 2,833–2,856 of 3,550 trials